🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPharmacology & MechanismsHas anyone dealt with molecular dynamics simulations of glp-1r binding?

Has anyone dealt with molecular dynamics simulations of glp-1r binding?

BrianDallas92 Wed, Apr 16, 2025 at 2:37 AM 36 replies 1,942 viewsPage 1 of 8
This thread is more than 13 months old. Information may be outdated. Consider searching for more recent discussions.
BrianDallas92
Member
312
1,456
Oct 2024
Dallas, TX
Apr 16, 2025 at 2:37 AM#1

Posting this because the summary going around does not say what the paper says, and the difference matters for how people here are using it.

The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

Where I think it is weakest: the subgroup findings are the part I trust least — with enough subgroups something is always significant, and these were not all pre-registered.

The narrow version of the question is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. Tell me what I have not thought of.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
23 18Dr.PathRoch, mona_PHX, andrew_nyc and 20 others
Reply Quote Save Share Report
Dr.PainCLE
Senior Member
1,234
6,234
Mar 2024
Cleveland, OH
Apr 16, 2025 at 3:00 AM#2
BrianDallas92 said:
The pharmacokinetics explain nearly every practical question asked here.

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing. Semaglutide:

  • Tmax: 24-72 hours post-injection
  • T½: ~168 hours (7 days) — enables weekly dosing
  • Steady state: reached at 4-5 weeks
  • Bioavailability (SubQ): ~89%
  • Volume of distribution: ~12.5L (primarily plasma)

The albumin binding (>99%) is the key pharmacological innovation — creating a sustained-release effect from a single injection. Previous GLP-1 agonists (exenatide) required BID dosing due to rapid clearance.

22 17tane_welly, Dr.PathRoch, mona_PHX and 19 others
Reply Quote Save Share Report
anders_CPH
Senior Member
1,567
7,234
Feb 2024
Copenhagen, DK
Apr 16, 2025 at 3:23 AM#3
BrianDallas92 said:
The pharmacokinetics explain nearly every practical question asked here.

Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

21 16AussieAnna, BethLabQueen, ChrisMacros and 18 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.NutriCornell
Senior Member
1,345
6,234
Mar 2024
Ithaca, NY
Apr 16, 2025 at 3:46 AM#4
anders_CPH said:
The mechanism is more central than most summaries suggest.

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].

Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.

Early-stage data — interpret with caution. But the trajectory is extraordinary.

References:
[1] Novo Nordisk investor presentation, September 2023.
20 15JenMemphis, pat_auckland, Dr.GastroMayo and 17 others
Reply Quote Save Share Report
Dr.EndoIndy
Member
267
1,234
Oct 2024
Indianapolis, IN
Apr 16, 2025 at 5:52 AM#5
Dr.PainCLE said:
PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing.

Second this.

19 14SandraNC_45, Dr.EndoIndy, tom_AK and 16 others
Reply Quote Save Share Report
1238

Similar Threads

GLP-1R desensitization — β-arrestin-mediated internalization18 replies
Biased agonism at GLP-1R — Gs vs β-arrestin signaling balance13 replies
Semaglutide albumin binding and the C-18 fatty acid linker17 replies
GIP receptor pharmacology — why GIP agonism enhances GLP-113 replies
Glucagon receptor signaling — hepatic glycogenolysis and lipolysis16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register